Light-Scattering Spectroscopy for Detection of Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01755208|
Recruitment Status : Recruiting
First Posted : December 24, 2012
Last Update Posted : May 25, 2018
|Condition or disease||Intervention/treatment||Phase|
|Healthy, no Evidence of Disease Stage II Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer||Procedure: light-scattering spectroscopy||Not Applicable|
PRIMARY OBJECTIVES: I. To evaluate whether light-scattering spectroscopy can reliably distinguish between two subject groups: those with clinical stage II or stage III breast cancer and those without breast cancer.
OUTLINE: Patients undergo light-scattering spectroscopy of the breast in addition to standard of care as it relates to screening for breast cancer or treatment of breast cancer.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||110 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Light-Scattering Spectroscopy for the Detection of Stage II-III Breast Cancer: A Pilot Study|
|Actual Study Start Date :||November 21, 2012|
|Estimated Primary Completion Date :||November 21, 2019|
|Estimated Study Completion Date :||November 21, 2020|
Experimental: Diagnostic (light-scattering spectroscopy)
Patients undergo light-scattering spectroscopy of the breast in addition to standard of care as it relates to screening for breast cancer or treatment of breast cancer.
Procedure: light-scattering spectroscopy
Undergo light-scattering spectroscopy
- Accurate classifications of women with or without breast cancer [ Time Frame: Up to 1 year ]Exact binomial probabilities will be used.
- Utility of optical markers in distinguishing cancer involved breasts from normal breasts [ Time Frame: Up to 1 year ]Multivariate analyses will be used.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01755208
|Contact: Pui Yan||323-865-3000||Puiyan@med.usc.edu|
|United States, California|
|USC Norris Comprehensive Cancer Center||Recruiting|
|Los Angeles, California, United States, 90033|
|Contact: Yan Pui 323-865-3000 Puiyan@med.usc.edu|
|Principal Investigator: Jacques Van Dam|
|Principal Investigator:||Jacques Van Dam||University of Southern California|